Estrella Immunopharma, Inc..
ESLA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Estrella Immunopharma, Inc. is a biopharmaceutical company focused on the research and development of innovative therapeutics for cancer and other unmet medical needs. The company's pipeline includes preclinical and clinical-stage drug candidates targeting various cancers. Estrella Immunopharma util...Show More
Better Health for All
30
Estrella Immunopharma's core business is dedicated to developing therapeutics for cancer, aiming to improve patient outcomes for life-threatening diseases. Early clinical trial results for its EB103 T-cell therapy show a complete response in the first patient treated for B-cell lymphoma and tumor response in all patients in the first dose cohort.
1
The company has maintained an outstanding safety record in its STARLIGHT-1 trial, with no dose-limiting toxicities or treatment-related serious adverse events observed in the first cohort.
2
The development of EB103, based on ARTEMIS technology, represents a significant investment in novel cancer treatment, with the investigational new drug application cleared by the FDA for a Phase I/II clinical trial.
3
Fair Money & Economic Opportunity
0
No evidence available to assess Estrella Immunopharma, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
The provided articles do not contain specific, quantitative data points for any of the KPIs under the 'Fair Pay & Worker Respect' value. Information regarding employee numbers indicates that Semnur had no full-time employees as of August 31, 2024, and Denali (the SPAC) had no full-time employees prior to its business combination, relying on a Transition Services Agreement for services from Scilex employees.
1
While CEO compensation for Cheng Liu is stated as US$250.0k, there is no data on median employee compensation to calculate a pay ratio.
2
Consequently, all KPIs must be omitted due to a lack of direct, verifiable evidence.
Fair Trade & Ethical Sourcing
0
No specific data or information regarding ESLA.US's performance on fair trade and ethical sourcing metrics, such as fair-trade certification share, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, spend on high-risk materials, or supplier diversity spend, was found in the provided articles.
1
Honest & Fair Business
0
No specific, concrete data points were found in the provided article to assess Estrella Immunopharma, Inc. against any of the 'Honest & Fair Business' KPIs.
Kind to Animals
-60
Estrella Immunopharma, Inc. conducts pre-clinical studies of its drugs on animals to assess product safety, and no formal animal testing policy is evidenced.
1
The company is collaborating with Imugene to develop a 'mark and kill' strategy for solid tumors,
2
but there is no indication that this collaboration is focused on developing animal-free testing methods or alternatives.
3
No War, No Weapons
0
Estrella Immunopharma, Inc. is consistently described across all provided articles as a biopharmaceutical company focused on the research and development of therapeutics for cancer and other medical needs.
1
Its activities encompass drug discovery, preclinical studies, clinical trials, and potential commercialization of pharmaceutical products. The articles explicitly state that the company's business is entirely focused on biopharmaceuticals and not on defense or arms-related activities.
2
Therefore, all KPIs related to military or defense involvement are scored as N/A, indicating no such activities in its core business or operations.
Planet-Friendly Business
0
No evidence available to assess Estrella Immunopharma, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence available to assess Estrella Immunopharma, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Estrella Immunopharma, Inc. (ESLA.US) has not identified any material cybersecurity threats or data breaches up to December 31, 2024, according to filings from March 2025 and September 2024.
1
The company outsources its IT support to a third-party provider that specializes in NIST compliance.
2
Two-factor authentication is implemented for access to data and email hosted on Office 365.
3
Email protection includes Exchange Online Protection, Data Loss Prevention, and basic email encryption.
4
Daily backups are conducted and monitored, with periodic restore tests.
5
Financial data access is restricted to relevant personnel on a dedicated SharePoint site.
6
However, the company has not conducted a formal standalone IT risk assessment and does not have a dedicated cybersecurity officer.
7
No specific details on vulnerability management processes or patching timeframes are provided.
8
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles regarding Estrella Immunopharma, Inc.'s performance on any of the Zero Waste & Sustainable Products KPIs.
1
All articles explicitly state that no data relevant to ESLA.US or zero waste/sustainable products could be extracted.
2